Satralizumab: A Review in Neuromyelitis Optica Spectrum Disorder
- PMID: 36933107
- DOI: 10.1007/s40263-023-00995-9
Satralizumab: A Review in Neuromyelitis Optica Spectrum Disorder
Abstract
Satralizumab (Enspryng®) is a monoclonal antibody that blocks the interleukin-6 (IL-6) receptor and is approved for the treatment of neuromyelitis optica spectrum disorder (NMOSD) in patients who are aquaporin-4 immunoglobulin G (AQP4-IgG) seropositive. Patients with NMOSD are at risk of recurrent autoimmune attacks that primarily target the optic nerves and spinal cord but may also target other regions of the central nervous system; these attacks can lead to life-long disability. In the randomized, placebo-controlled phase III SAkuraSky and SAkuraStar trials, subcutaneous satralizumab as an add-on to immunosuppressive therapy or as a monotherapy, respectively, significantly reduced the risk of relapse compared with placebo in patients who were AQP4-IgG seropositive with NMOSD. Satralizumab was well tolerated; the most common adverse events were infection, headache, arthralgia, decreased white blood cell count, hyperlipidaemia and injection-related reactions. In the EU, satralizumab is the first IL-6 receptor blocker to be approved for treatment of AQP4-IgG-seropositive patients with NMOSD, has the potential advantage of subcutaneous administration, and is the only targeted treatment approved for adolescent patients with this disorder. Thus, satralizumab is a valuable treatment option for patients with NMOSD.
Plain language summary
Neuromyelitis optica spectrum disorder (NMOSD) is an autoimmune disorder, in which recurrent attacks by the body’s own immune system can cause severe morbidity and disability. Immunoglobulin G antibodies targeting the aquaporin-4 (AQP4-IgG) water channel in cells of the central nervous system can be detected in the majority of patients with NMOSD. Satralizumab (Enspryng®), which is designed to suppress autoantibody production by blocking the interleukin-6 (IL-6) receptor, was found to significantly reduce the rate of immune attack recurrence compared with placebo when used as an add-on to standard immunosuppressive therapy (SAkuraSky trial) or when used alone (SAkuraStar trial). Satralizumab was well tolerated in the SAkuraSky and SAkuraStar trials, with infections (e.g. nasopharyngitis, upper respiratory tract infections) being the most common associated adverse event. In the EU, satralizumab is the first IL-6 receptor blocker approved for AQP4-IgG-seropositive patients with NMOSD and is the only subcutaneously administration targeted drug approved for NMOSD. Therefore, satralizumab represents a valuable treatment option for NMOSD.
© 2023. The Author(s), under exclusive licence to Springer Nature Switzerland AG.
Similar articles
-
Long-term Efficacy of Satralizumab in AQP4-IgG-Seropositive Neuromyelitis Optica Spectrum Disorder From SAkuraSky and SAkuraStar.Neurol Neuroimmunol Neuroinflamm. 2022 Dec 8;10(1):e200071. doi: 10.1212/NXI.0000000000200071. Print 2023 Jan. Neurol Neuroimmunol Neuroinflamm. 2022. PMID: 36724181 Free PMC article. Clinical Trial.
-
Trial of Satralizumab in Neuromyelitis Optica Spectrum Disorder.N Engl J Med. 2019 Nov 28;381(22):2114-2124. doi: 10.1056/NEJMoa1901747. N Engl J Med. 2019. PMID: 31774956 Clinical Trial.
-
SAkuraBONSAI: Protocol design of a novel, prospective study to explore clinical, imaging, and biomarker outcomes in patients with AQP4-IgG-seropositive neuromyelitis optica spectrum disorder receiving open-label satralizumab.Front Neurol. 2023 Feb 17;14:1114667. doi: 10.3389/fneur.2023.1114667. eCollection 2023. Front Neurol. 2023. PMID: 36873431 Free PMC article.
-
Inebilizumab: A Review in Neuromyelitis Optica Spectrum Disorder.CNS Drugs. 2022 Oct;36(10):1133-1141. doi: 10.1007/s40263-022-00949-7. Epub 2022 Sep 7. CNS Drugs. 2022. PMID: 36070074 Free PMC article. Review.
-
Advances in the long-term treatment of neuromyelitis optica spectrum disorder.J Cent Nerv Syst Dis. 2024 Feb 1;16:11795735241231094. doi: 10.1177/11795735241231094. eCollection 2024. J Cent Nerv Syst Dis. 2024. PMID: 38312734 Free PMC article. Review.
Cited by
-
Association Between Serum Interleukin-32 Level and Disease Status in Cases with Neuromyelitis Optica Spectrum Disorders.J Inflamm Res. 2024 Aug 26;17:5645-5652. doi: 10.2147/JIR.S476435. eCollection 2024. J Inflamm Res. 2024. PMID: 39219816 Free PMC article.
-
Monoclonal antibodies in neuro-ophthalmology.Saudi J Ophthalmol. 2024 Mar 29;38(1):13-24. doi: 10.4103/sjopt.sjopt_256_23. eCollection 2024 Jan-Mar. Saudi J Ophthalmol. 2024. PMID: 38628411 Free PMC article.
-
Review of Satralizumab for Neuromyelitis Optica Spectrum Disorder: A New Biologic Agent Targeting the Interleukin-6 Receptor.Cureus. 2024 Feb 27;16(2):e55100. doi: 10.7759/cureus.55100. eCollection 2024 Feb. Cureus. 2024. PMID: 38558672 Free PMC article. Review.
-
Intruders or protectors - the multifaceted role of B cells in CNS disorders.Front Cell Neurosci. 2024 Jan 10;17:1329823. doi: 10.3389/fncel.2023.1329823. eCollection 2023. Front Cell Neurosci. 2024. PMID: 38269112 Free PMC article. Review.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources